Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
BioSig Technologies, Inc. develops advanced medical device technology focused on electrophysiology (EP) with its PURE EP™ Platform, which enhances real-time cardiac signal acquisition and analysis during catheter ablation of complex arrhythmias like atrial fibrillation and ventricular tachycardia. Serving electrophysiologists and EP labs, BioSig’s platform improves signal clarity and procedural precision, aiming to optimize ablation outcomes through proprietary hardware and software integrated into existing clinical workflows.
This description was generated via AI from an annual report. Updated about 1 year ago.